Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer  https://t.co/XblIN4rkKM  https://t.co/v0cSRnzxF6